Objective: The objectives of this study were to investigate the effect of age on pharmacokinetic parameters of lamotrigine (LTG) and estimate parameter variability. Methods: Patients (>18 years old) who were already on a steady-state dose of LTG therapy with no interacting comedications were enrolled. Patients with significant cardiac disease, severe kidney dysfunction, or moderate-to-severe liver dysfunction were excluded. Fifty milligrams of a stable-labeled intravenous LTG formulation (SL-LTG) replaced 50 mg of a patient's normal daily oral LTG dose.
LTG pharmacokinetics have been well characterized in adult healthy volunteers and adult patients with epilepsy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The immediate release LTG oral formulation is rapidly absorbed, with negligible first-pass metabolism, and has a bioavailability of 98% in healthy volunteers. LTG is a low-clearance drug and is extensively (~90%) metabolized via glucuronidation by UGT1A4. 8, 11 It is moderately protein bound (55%) 8 and has a relatively long half-life (23-37 hours). [4] [5] [6] [7] [8] [9] [10] The prevalence of epilepsy in elderly patients is higher than in the young adult population. 12 LTG is better tolerated in elderly patients than some other antiseizure drugs. 13, 14 In addition, LTG has a low propensity to cause drug interactions, because it is primarily glucuronidated and does not inhibit or induce cytochrome P450 enzymes. Age-related physiological changes in the elderly may affect drug disposition characteristics such as absorption, distribution, metabolism, and elimination. 15 Therefore, LTG pharmacokinetics may differ between young (18-60 years old) and elderly (>60 years old) adult patients. Studies comparing the pharmacokinetic characteristics between young and old adult populations 5, 16 involved healthy volunteers and retrospective data collection. Detailed information on LTG pharmacokinetics has also been limited to oral dosing due to the unavailability of an intravenous (IV) formulation. A stable isotope methodology allows simultaneous administration of IV and oral LTG under steady-state conditions without disrupting maintenance therapy in patients. Therefore, the methodology permits rigorous characterization of LTG pharmacokinetics in a clinically relevant setting. The methodology allows accurate determination of absolute bioavailability, clearance, volume of distribution, and elimination half-life in patients on regular maintenance therapy. The objectives of the analysis were to determine the pharmacokinetic parameters of LTG, quantify the effect of age on LTG clearance, and estimate parameter variability in the study population using oral and IV formulations permitting the determination of absolute bioavailability at steady-state dosing.
| MATERIALS AND METHODS
The study protocol was approved by the respective institutional review boards of three epilepsy research centers: the University of Minnesota, the University of Miami, and Emory University. Consent to participate was obtained from all subjects. Use of stable-labeled LTG (SL-LTG; 13 C 2 , 15 N-LTG) was approved by the US Food and Drug Administration (Investigational New Drug Application #72 642).
| Study population
The subjects were young (18-50 years of age) and elderly (>60 years of age) adult epilepsy patients on a stable chronic therapy of LTG. Inclusion criteria for patients were either LTG monotherapy or with other noninteracting antiepileptic drugs and a stable maintenance regimen of LTG for at least 2 weeks. Exclusion criteria were patients with significant cardiac disease, those with possibly interfering medications, those with clinical evidence of severe kidney dysfunction, and those with moderate-to-severe liver dysfunction as determined by routine clinical testing (alanine aminotransferase or aspartate aminotransferase 3× upper limit of normal). The study was performed at the general clinical research centers of the three participating epilepsy research centers.
| Study design
Subjects fasted from midnight until admission to the general clinical research center the day of the study and were instructed not to take their morning oral LTG doses. Upon admission to the general clinical research center, a neurological examination was performed, and medical and medication histories were recorded. One blood sample was obtained prior to drug administration for predose concentration measurement and for basic clinical laboratory screening, including measures of kidney (blood urea nitrogen and serum creatinine) and liver function (alanine aminotransferase, aspartate aminotransferase, and bilirubin). Fifty milligrams of IV SL-LTG (10 mg/mL in 30% wt/vol 2-hydroxypropyl-β-cyclodextrin) were diluted with normal saline to a final volume of 15 mL and infused at a rate of 1 mL/min. Following the infusion, patients were given their usual morning LTG oral dose (Lamictal tablets; GlaxoSmith Kline, Brentford, UK) minus 50 mg. The IV infusion of SL-LTG to patients has been demonstrated to be well tolerated, with no adverse events and no changes in vital signs. 17 This study included data only from patients taking the branded, immediate release tablet formulation. Blood samples for the determination of intensive LTG and SL-LTG pharmacokinetics were collected predose and at 13 time points up to 96 hours postdose. The samples
Key Points
• Measurement of clearance and absolute bioavailability at steady-state dosing with a stable-labeled intravenous LTG formulation • Absolute bioavailability for LTG tablets was 73.9% in both young and elderly adult patients at steady-state dosing • LTG clearance was 27.2% lower in elderly than in young adult epilepsy patients were centrifuged within 2 hours of collection, and plasma was stored at −80°C until analysis.
| Simultaneous assay of LTG and SL-LTG
Plasma samples were analyzed on a previously described validated gas chromatography-mass spectrometry simultaneous assay for the determination of LTG and SL-LTG concentrations. 18 All samples from an individual patient were analyzed in a single batch and compared against a triplicate standard curve ranging from 0.25 to 20 μg/mL for LTG concentrations and 0.025-2 μg/mL for SL-LTG concentrations. Triplicates of low-, medium-, and high-quality control samples were employed in the analysis of each run. Values of quality samples were considered acceptable if the accuracy (% bias) was within ±15% and precision (coefficient of variation) was <15%. 19 
| Population pharmacokinetic modeling
All observations from oral and IV administrations were combined into a single database for analysis by nonlinear mixed-effects modeling (NONMEM version 7.3; ICON Development Solutions, Ellicott City, Maryland). Diagnostic plots were constructed with the R statistics software (version 3.2.2)
. 20 An open one-compartment model (subroutines ADVAN2, TRANS2) and a two-compartment model (subroutines ADVAN4, TRANS4) 21 were investigated to select a pharmacokinetic structural model that best described the LTG concentration-time data. The first-order conditional estimation method with η-ε interaction was employed for all model runs. Both IV and oral data were simultaneously analyzed. The structural models were provided parameters in terms of clearance (CL), central volume of distribution (V c ), absorption rate constant (k a ), absolute bioavailability (F), the two-compartment model intercompartmental clearance (Q), and peripheral volume of distribution (V p ). Between-subject variability in the pharmacokinetic parameters was modeled with an exponential error model. This imparts a lognormal distribution on the parameter of interest, and variability is interpreted as a percentage coefficient of variation. Residual unexplained variability (RUV) is a quantity that explains the variability around each predicted concentration. RUV was explored with additive, proportional, and combined proportional and additive error models. Because IV and oral concentrations were measured with different dynamic ranges by gas chromatography-mass spectrometry and were modeled simultaneously, separate RUV models were examined for IV and oral data.
| Modeling age as a covariate
To account for the distribution phase, a two-compartment model is needed that requires four pharmacokinetic parameters-two for clearance including apparent intercompartmental clearance (Q) and two for volume including volumes for both a central (V c ) and peripheral compartment (V p ). The clearances (CL and Q) and volumes (V c and V p ) were allometrically scaled using body weight. The exponents on CL and Q were fixed to 0.75, whereas the exponents on V p and V c were fixed to 1. 22 Due to the limited sample size of this study, covariate analysis was limited to the effect of age. In addition, due to the distribution of ages in the cohort, age was converted from a continuous variable to a binary variable (elderly vs young adults , P < 0.05, df = 1) was considered significant.
| Model evaluation
Model evaluation was guided by various goodness-of-fit criteria including diagnostic scatter plots, plausibility of parameter estimates, and precision of parameter estimates. A nonparametric bootstrap procedure was used for model evaluation. One thousand datasets were generated by random sampling with replacement from the original dataset. The final model was used to estimate population parameters for each bootstrap dataset. The bootstrap results were pooled only from the runs with successful convergence. The 2.5th, 50th, and 97.5th percentiles of the parameter distributions were computed and compared with the results from the population analysis. In addition, the final model was qualified by examining visual predictive check (VPC) plots 23 separately for oral LTG and IV SL-LTG. A standard VPC was used for the IV SL-LTG, whereas a prediction-corrected VPC was used for oral LTG, because maintenance doses of LTG varied across subjects. The final model parameter estimates were used to simulate 1000 replicates of the original dataset. The 5th, 50th, and 95th percentiles of the observed data were calculated. These were compared to the corresponding percentile 95% prediction interval bands of the simulated data.
| RESULTS

| Study population
Intensive concentration-time data from simultaneous oral and IV administration of LTG and SL-LTG in 16 young and 12 elderly adult epilepsy patients were included in the population pharmacokinetic analysis. LTG daily doses ranged from 200 to 800 mg. Patient demographic information is shown in Table 1 . The dataset included a total of 382 oral and 351 IV concentrations, because some of the IV concentrations were below the lower limit of quantification, as they reflected levels after a single tracer dose. The population consisted of 68% women (68%). Twenty-seven subjects were Caucasian, and one was of African American descent. Distribution of body weight was similar between young and elderly patients. Creatinine clearance in young adult patients was higher than in the elderly adult patients (107 vs 58 mL/min), which is consistent with decreased renal function in the elderly population. The majority of the elderly patients had mildto-moderate renal impairment (creatinine clearance rate: 35-103 mL/min) as defined by US Food and Drug Administration guidelines. 
| Population pharmacokinetic analysis
A two-compartment model with first-order absorption and elimination adequately described the plasma concentrationtime data. The scatter plots of observed concentrations versus time after dose stratified by oral LTG and IV SL-LTG doses are presented in Figure 1A and 1B, respectively. Each structural pharmacokinetic parameter including its between-subject variability was successfully estimated. The RUV evaluation resulted in a single proportional error model that adequately described both the LTG (oral) and SL-LTG (IV) concentrations. No additional benefit in terms of the Akaike information criterion and diagnostic plots was observed with additive, combined additive and proportional, or two separate RUV error models for LTG and SL-LTG concentrations. Age (as a binary variable, elderly vs young adults) only had a significant effect on CL in the final model. All other parameters including F were not affected by age. The final model parameter estimates, including precision of the estimates, are presented in Table 2 and represent values for a typical 70-kg individual. For example, the population mean of LTG CL for a 70-kg young epilepsy patient was 1.80 L/h. On average, elderly patients had a 27.2% lower CL than young patients. The bioavailability of the tablet formulation of LTG compared to the IV formulation was estimated by the model to be 73.9%.
T A B L E 1 Demographic characteristics of the patients
Patient characteristics
All subjects, n = 
| Model evaluation
Goodness-of-fit plots for oral LTG and IV SL-LTG are presented in Figures S1 and S2 . The diagnostic plots revealed that the final model was consistent with the observed data. Plots of conditional weighted residuals were generally well scattered across the range of predicted concentrations ( Figures S1C and S2C ) and time after dose ( Figures S1D and S2D ), indicating no overall systematic bias in the model diagnostics. The results of the bootstrap procedure (714 successful runs) are presented in Table 2 . The estimated model parameters from the population analysis and medians from the bootstrap analysis were highly comparable. Furthermore, 95% confidence intervals of the population parameters were comparable to the bootstrap 2.5th and 97.5th percentiles. Thus, the model evaluation indicates accuracy and precision of parameter estimates as well as stability of the model. The prediction-corrected VPC plots of oral LTG and IV SL-LTG are shown in Figure 2A and 2B. These figures suggest that the model predicts the data reasonably well, as the 5th, 50th, and 95th percentile lines are contained within the respective 95% prediction intervals of the simulated data.
| DISCUSSION
The availability of an intravenous stable-labeled LTG formulation formulated by our group made rigorous characterization of LTG pharmacokinetics possible in patients during steady-state therapy. We found LTG CL differed between young and elderly adult patients with epilepsy. We found no difference in F for the LTG tablets between the two age groups. The F for the LTG tablets for both young and elderly adult epilepsy patients was 73.9%. This value is consistent with the F reported (73%) by our group for the same LTG formulation (immediate release tablet) in these elderly patients using a noncompartmental analysis. 18 There is limited information available reporting absolute bioavailability, as there is no intravenous LTG product commercially available. A previous study of the bioavailability of LTG from a single dose study in a group of eight healthy volunteers (20-35 years old) given an IV LTG isethionate salt preparation and oral LTG gelatin capsules reported an F value of 98%. 7 The differences in F values could be due to the differences between the oral formulations (tablets vs capsules). In our study, the use of SL-LTG allowed for more reliable evaluation of F in patients on maintenance therapy with simultaneous IV and oral tablet administration and avoided limitations of the classic two-period crossover design. We found LTG CL to be influenced by age (young [18-48 years] vs elderly [63-87 years]), with elderly patients having an average of 27.2% lower CL than young adults of comparable body weight. Similarly, previous studies in healthy volunteers and patients with epilepsy reported a 37% decrease in oral CL (intensive single dose oral pharmacokinetics; elderly [n = 12, 65-76 years old] vs young [n = 12, 26-38 years old]) and a 20% lower LTG oral CL in old compared to young adults (retrospective outpatient study; old [n = 155, 55-92 years old] vs young [n = 247, 16-36 years old]), respectively. 5, 16 Age-related changes in liver mass could explain the difference in CL between the elderly and young adult patients. 25, 26 However, given the low extraction ratio and moderate protein binding (55%) characteristics of LTG, we expect the reduction in CL to be mainly caused by the reduced UGT1A4 expression and/ or liver mass in the elderly group. 25, 26 It has often been assumed that age has no effect on glucuronidation. 27 The hypothesis was based on pharmacokinetic studies of lorazepam and oxazepam by Greenblatt and coworkers conducted in the late 1970s prior to identification of multiple UGT isoforms. 28, 29 Lorazepam and S-oxazepam are UGT2B15
substrates, and R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. [30] [31] [32] In contrast, the major UGT1A family enzyme responsible for lamotrigine N-glucuronidation is UGT1A4, with a minor contribution by UGT1A3. 33 Minor metabolites are also produced by P450 enzyme involvement. 34 In vitro studies with human liver microsomes indicate that UGT2B7 may also contribute based on inhibition of LTG glucuronidation by azidothymidine and valproic acid, known UGT2B7 inhibitors, although kinetic studies with cloned, expressed UGT2B7 are lacking. 33, 35 Two nonsynonymous polymorphisms in UGT1A4 have been identified in whites with a frequency of 0.07-0.10. In vitro, the P24T and L84V variants displayed a reduced in vitro clearance of~50% of wild-type UGT1A4. 36 Genotypic information was not available in the individuals in this study. Polymorphism in UGT1A4 and UGT2B7 has been shown to have either a modest (≤25%) or no effect on LTG clearance in vivo. [37] [38] [39] [40] Minor oxidative pathways to an N-oxide and to a reactive arene oxide metabolite have been demonstrated in vivo in rats 41 and in vitro. 34 In addition, oxidation of the dichlorophenyl ring in the presence of glutathione by human liver microsomes or CYP2A6 or CYP2D6 formed trapped glutathionyl conjugates. 34 Therefore, although UGT1A4 is thought to be responsible for the majority of LTG's metabolism, the involvement of P450 enzymes could contribute to an age effect. However, none of these enzymes responsible for LTG metabolism is shown to have reduced activity with age. 42 Thus, the decrease in liver mass could be assumed for the decrease in CL in the elderly. In addition, individual UGT probes may show age-selective differences in expression and should not be generalized to a single conjugation (phase II metabolism). The plasma concentration-time profiles of oral LTG and IV LTG were adequately described by a two-compartment pharmacokinetic model. Previous population pharmacokinetic studies [43] [44] [45] [46] [47] described LTG pharmacokinetics by a one-compartment model; however, the studies did not include IV pharmacokinetic data in the analyses. The final population estimate for k a in our study was 0.591 h −1 and is within the range (0.38-3.57 h −1 ) reported in the literature. 8, 45, 46 The between-subject variability in k a was 256%, indicating that there is substantial variability in absorption between individuals. This large variability is consistent with previous analyses. 24, 44 A steady-state volume of distribution was calculated as a sum of the apparent central (V c /F) and peripheral (V p /F) volumes of distribution and was found to be approximately 62.3 L. This is in comparison with the apparent volume of distribution (V/F) values (77.1-132 L) reported in the literature 4, 5, 7, 8, [44] [45] [46] [47] calculated from noncompartmental analyses. A mean terminal half-life (t 1/2β ) of LTG was derived from the final model parameter estimates for both young and elderly adult epilepsy patients. The mean terminal half-life was 24.7 hours for young and 33.6 hours for elderly adult epilepsy patients. This is similar to the finding presented by Posner et al that on average elderly subjects have a 7-hour longer terminal half-life compared to the young adult subjects. The magnitude of RUV was expressed as % CV = sqrt(σ 2 ) * 100.
| CONCLUSION
Although we found no difference in LTG bioavailability of the oral tablets between the two age groups, LTG CL in the elderly was 27.2% lower than in young adult patients with epilepsy. The long half-life in elderly indicates that one time per day in elderly individuals may simplify the medication regimen and enhance medication adherence. Additionally, these findings suggest that the clinician could consider a lower initial target dose in the elderly, followed by assessment of clinical response (seizure control vs side effects) and/or serum concentration measurements compared to the initial target dose in the young adult patients. Given the rising prevalence of epilepsy in the elderly population, these findings are particularly relevant for clinicians to provide optimal epilepsy care and support the general concept of starting with lower doses in elderly patients.
